1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/site_map/index.html

Site Map

Home

Patients & Caregivers

• Basics
  
• Pre-Transplant Process
  
• Transplant Process
  
• Post-Transplant Process
  
• Planning for a Transplant
  
• Finances
  
• Patient Handouts
  

Clinical Trials

• 02057 - A Randomized Trial of Neulasta (Pegfilgrastim) Versus Neupogen (Filgrastim) to Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma
  
• 03047 A Phase II Open-label Trial of VELCADE in VELCADE-naive Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed By Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response
  
• 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial
  
• 1591 Campath - Alemtuzumab Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients with Hematologic Malignancies - A Multi-Center Trial
  
• 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial
  
• 1959 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
  
• 1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia
  
• A Treatment Guideline for High-Dose Melphalan with Autologous Hematopoietic Stem Cell Reconstitution for Primary Systemic Amyloidosis
  
• An Open-Label, Multi-Center, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/ Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
  
• CLOSED AMD3100-3101 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 μg/kg) Plus G-CSF (10 μg/kg) Versus G-CSF (10 μg/kg) Plus Placebo to Mobilize and Collect ≥ 5x 10⁶ CD34+ Cells/kg in Non-Hodgkin Lymphoma Patients for Autologous Transplantation
  
• CLOSED AMD3100-3102 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240mcg/kg) plus G-CSF (10mcg/kg) Versus G-CSF (10mcg/kg) Plus Placebo to Mobilize and Collect >6 x 106 CD34+ Cells/Kg in Multiple Myeloma Patients for Autologous Transplantation.
  
• CLOSED E1402 - A Phase II Study of Reduced Intensity (Nonmyeloablative) Allogeneic Bone Marrow Transplantation for the Treatment of Relapsed Non-Hodgkin and Hodgkin Lymphoma
  
• CLOSED E2499 Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma.
  
• CLOSED E2993 Phase III Randomized Trial of Autologous And Allogeneic Bone Marrow Transplantation Versus Intensice Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission
  
• CLOSED PO2095 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections
  
• CLOSEDE1900 A Phase III Trial in Adult Myeloid Leukemia: Daunorubicin Dose-Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy Prior to Autologous Stem Cell Transplantation.
  
• CTN-0102 A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma
  
• Cyclophosphamide and Antithymocyte Globulin, With or Without Total Body Irradiation, Followed By Allogeneic Hematopoietic stem Cell Transplantation For Severe Aplastic Anemia
  
• Defibrotide For the Treatment of Severe Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety and Efficacy
  
• EFC4978 Evaluation of Single Agent Raburicase for 5 Days Versus Sequential Treatment with Rasburicase from Day 1 Through 3 Followed by Oral Allopurinol from Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients with Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome
  
• EFC5339 Evaluation of Single Agent Rasburicase in Treatment/ Prevention Associated with Tumor Lysis Syndrome in Adult and Pediatric Patients with Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease
  
• High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplant As Rescue Therapy for Multiple Myeloma
  
• Prevention of Nephrotocity Following Allogeneic Bone Marrow Transplantation using Urodilatin (Ularitide, Atrial Natriuretic Peptide) and Mannitol
  
• Reconstitution of Innate and Adaptive CMV Immunity in Recipients of Allogeneic Bone Marrow Transplant
  
• Rocky Mountain Blood and Marrow Transplant Program Busulfan and Cyclophosphamide Followed By Hematopoietic Stem Cell Transplantation:
  
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants
  
• Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol
  
• Treatment Of Germ Cell Tumors With ICE High-Dose Chemotherapy And Autologous Stem Cell Rescue
  
• Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol
  
• Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Followed by Allogeneic Marrow or Peripheral Blood Stem Cell Transplantation
  
• Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue
  
• Urine Characteristics of Chronic Renal Dysfunction Following Myeloablative and Non-Myeloablative Hematopoietic Cell Transplantation
  

Program Statistics

Referrals

Continuing Care

Diseases

• Acute Lymphocytic Leukemia (ALL)
  
• Acute Myeloid Leukemia (AML)
  
• Amyloidosis
  
• Aplastic Anemia
  
• Chronic Lymphocytic Leukemia (CLL)
  
• Chronic Myeloid Leukemia (CML)
  
• Hodgkin Lymphoma
  
• Multiple Myeloma
  
• Myelodysplastic Syndrome (MDS)
  
• Non-Hodgkin Lymphoma (NHL)
  
• Testicular Cancer
  

Patient Stories

• Bob Heykoop
  
• George Poynter
  
• Janice Gangl
  
• Leslie Szabo
  
• Maggie Brunner
  
• Wayne Marrone
  

News

• Investigators publish new data in the report "Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia."
  
• Novel therapies that target Rap1 could potentially be used to treat leukemias caused by BCR/ABL
  
• Sprycel® (Dasatinib) Confirmed Effective for Gleevec-Resistant Patients with Chronic Myeloid Leukemia (CML)
  
• Surgery Earlier In Life Reduces Risk of Testicular Cancer Among Males with Undescended Testis
  
• 'Mini transplant' patients' outcomes similar using related and unrelated donor cells
  
• 'Modular' leukemia drug shows promise in early testing
  
• 2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate (Atiprimod) induced apoptosis in multiple myeloma (MM) cells
  
• 3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
  
• 3-substituted benzamide derivatives could be used to treat chronic myeloid leukemia (CML)
  
• A case of donor cell-derived acute leukemia occurred following umbilical cord blood transplantation
  
• A denaturing high-performance liquid chromatography (DHPLC) assay could be used to identify NPM1 mutations in leukemia
  
• A denaturing high-performance liquid chromatography (DHPLC) assay could be used to identify NPM1 mutations in leukemia
  
• A Disease Affecting White Blood Cells, the Body’s Infection Fighters
  
• A faster way to recover from chemotherapy and marrow transplant
  
• A higher risk of childhood leukemia, particularly of acute lymphoblastic leukemia (ALL), was linked to high magnetic field (MF) exposure
  
• A molecular-based mechanism for restriction of the leukemic phenotype to the CD4+ T cell subtype was described
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new chronic myeloid leukemia (CML) staging system was proposed
  
• A new erythroblastic leukemia cell line revealed
  
• A new study, "Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "B-1 B cells: development, selection, natural autoantibody and leukemia," is now available
  
• A new study, "Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)," is now available
  
• A new study, "Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)," is now available
  
• A new study, "Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up
  
• A new study, "Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors," is now available
  
• A new study, "One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near,&
  
• A new study, "Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan," is now available
  
• A new study, "p21 delays tumor onset by preservation of chromosomal stability," is now available
  
• A new study, "The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells," is now available
  
• A novel intradermal idiotype vaccine elicited specific immune responses in patients with advanced B-cell lymphoma despite profound immunosuppression
  
• A recent study from Canada has reported that the TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "End points to establish the efficacy of new agents in the treatment of acute leukemia," is newly published data in Blood
  
• A report, "Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia," is newly published data in International Journal of Hematology
  
• A report, "The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid," is newly published data in The Journal of Virology
  
• A researcher reviews vaccination for leukemia in a recent issue of Biology of Blood and Marrow Transplantation
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A set of 7 genes have been identified that can be used to monitor minimal residual disease in pediatric acute myeloid leukemia
  
• A severe combined immunodeficient mouse model enables rapid evaluation of treatments for multiple myeloma
  
• A simplified flow cytometric assay was developed that could identify a high proportion of children with acute lymphoblastic leukemia (ALL) who would have an excellent early treatment response and a high likelihood of cure
  
• A simplified flow cytometric assay was developed that could identify a high proportion of children with acute lymphoblastic leukemia (ALL) who would have an excellent early treatment response and a high likelihood of cure
  
• A study by cancer researchers reveals that a new strain of mice offers the first real animal model for an incurable form of chronic leukemia and should greatly aid the development of new drugs for the disease
  
• A triple purge strategy eliminates chronic myelogenous leukemia cells from autografts
  
• A triple purge strategy eliminates chronic myelogenous leukemia cells from autografts
  
• Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
  
• Abbott introduces CE-marked DNA tests in Europe to detect leukemia
  
• AC133 positive leukemia cells could be prognosticated by expression of the myeloperoxidase (MPO) gene
  
• AC133 positive leukemia cells could be prognosticated by expression of the myeloperoxidase (MPO) gene
  
• According to a study from Australia, C-II amyloid fibrils are bound by high density lipoproteins
  
• According to a study from France, chronic lymphocytic leukemia (CLL) cell survival is promoted by high Mda-7 expression
  
• According to a study from Germany, BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells
  
• According to a study from Germany, gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia (CML) blast crisis
  
• According to a study from Japan, suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma (MM) cells
  
• According to a study from the Netherlands, signal transducer and activator of transcription 5 (STAT5)-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP alpha
  
• According to a study from the United States, consolidation of high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compa
  
• According to a study from the United States, consolidation of high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compa
  
• According to a study from the United States, leukemia-associated gain-of-function mutation affects interleukin-3 (IL-3) signaling
  
• According to a study from the United States, leukemia-associated gain-of-function mutation affects interleukin-3 (IL-3) signaling
  
• According to a study from the United States, phosphoproteomic analysis of acute myeloid leukemia (AML) cell lines identifies leukemic oncogenes
  
• According to a study from the United States, phosphoproteomic analysis of acute myeloid leukemia (AML) cell lines identifies leukemic oncogenes
  
• According to recent research from France, human T-cell leukemia virus type 1 (HTLV-1) infected cell fusion with dendritic cells (DCs) is facilitated by DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN)
  
• According to recent research from the United States, a human T-cell leukemia virus type 1 (HTLV-1) motif participates in Gag targeting and particle release
  
• According to recent research from the United States, c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
  
• According to recent research published in the journal Clinical and Experimental Dermatology, malignant melanoma (MM) expresses endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF)
  
• According to recent research published in the journal Molecular Cancer Therapeutics, myeloma cell caspase-dependent apoptosis and cell cycle inhibition is induced by the IMP dehydrogenase (IMPDH) inhibitor mycophenolate mofetil (MMF)
  
• According to recently published research from the People's Republic of China, inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis
  
• According to recently published research from the United States, human leukemic cells are affected by a synthetic triterpenoid, C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me)
  
• Activated M-Ras expression in hematopoietic stem cells initiates leukemogenic transformation
  
• Acute (AML) and chronic myeloid leukemia (CML) pathogenesis could be linked to abnormal expression of the programmed cell death 5 (PDCD5) gene
  
• Acute lymphoblastic leukemia (ALL) cells respond to thalidomide analogue CC-4047
  
• Acute lymphoblastic leukemia (ALL) could be treated by short-course high-dose methylprednisolone (HDMP) instead of prednisolone
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia (ALL) poor prognosis could be linked to ASPP1 gene promoter expression
  
• Acute lymphoblastic leukemia cells respond to thalidomide analogue CC-4047
  
• Acute lymphoblastic leukemia poor prognosis predicted by Aven overexpression
  
• Acute lymphoblastic leukemia prognosticated by CALCA promoter hypermethylation
  
• Acute lymphoblastic leukemia remission is likely when lymphangiogenesis factor is absent
  
• Acute myelogenous leukemia (AML) could be linked to JAK2 V617F mutation
  
• Acute myeloid leukemia (AML) could be managed on an outpatient basis
  
• Acute myeloid leukemia (AML) could be prognosticated by the size of FLT3 internal tandem duplication (FLT3/ITD)
  
• Acute myeloid leukemia (AML) is detected by angiogenesis biomarkers
  
• Acute myeloid leukemia (AML) patients with KIT-D816 mutations were associated with poor prognosis
  
• Acute myeloid leukemia (AML) patients with KIT-D816 mutations were associated with poor prognosis. "Mutations in codon D816 of the KIT gene represent a recurrent genetic alteration in AML
  
• Acute myeloid leukemia (AML) patients with normal cytogenetics could be prognosticated by BAALC expression
  
• Acute myeloid leukemia (AML) was associated with cyclin A1 expression
  
• Acute myeloid leukemia (AML) with t(8;21)(Q22;q22) is linked to frequent expression of B cell-specific activator protein (BSAP), whereas PAX5 silencing is not required for myeloid differentiation
  
• Acute myeloid leukemia (AML) with t(8;21)(Q22;q22) is linked to frequent expression of B cell-specific activator protein (BSAP), whereas PAX5 silencing is not required for myeloid differentiation
  
• Acute myeloid leukemia and myelodysplastic syndrome find new target of 11q amplification in GAB2
  
• Acute myeloid leukemia cell beta-catenin expression predicts poor prognosis
  
• Acute myeloid leukemia infants have high incidence of t(7;12)(q36;p13)
  
• Acute myeloid leukemia is detected by angiogenesis biomarkers
  
• Acute myeloid leukemia patients 50 years of age or older responded to induction therapy
  
• Acute myeloid leukemia progression prognosticated by serum levels of sCD137
  
• Acute myeloid leukemia was associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque
  
• Acute myeloid leukemia was associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque
  
• Acute myeloid leukemia-associated MLL partial tandem duplications persist lifelong
  
• Adding Radioimmunotherapy To Chemo May Help Patients With Lymphoma
  
• Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
  
• Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma
  
• Administration of short course, high dose methylprednisolone (HDMP) might improve endothelial dysfunction caused by acute lymphoblastic leukemia (ALL)
  
• Adolescent survivors of childhood acute lymphoblastic leukemia (ALL) reported difficulties in overcoming psychological and physical pain
  
• Adolescent survivors of childhood acute lymphoblastic leukemia (ALL) reported difficulties in overcoming psychological and physical pain
  
• Adult acute lymphoblastic leukemia patients with dic(7:9) demonstrate a consistent phenotype
  
• Adult acute megakaryocytic leukemia (FAB M7 AML) was confirmed to have a poor prognosis
  
• Adult B-lineage acute lymphoblastic leukemia (ALL) could be managed by a flow cytometric approach to minimal residual disease (MRD) monitoring
  
• Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
  
• Adult T-cell leukemia (ATL) could be treated by curcumin
  
• Adult T-cell leukemia/lymphoma (ATLL) progression was linked to the down-regulation of ASY/Nogo transcription
  
• Advanced Hodgkin lymphoma (HL) patients did not benefit more from radiotherapy (RT) than consolidation chemotherapy (CT) after a doxorubicin-induced CR
  
• Advanced therapy offers cure for relapsed cancer patient
  
• Advances in the reduction of mortality from childhood acute myeloid leukemia (AML) were reviewed
  
• Advances in the reduction of mortality from childhood acute myeloid leukemia (AML) were reviewed
  
• Aegera Therapeutics Acquires Clinical Stage Oncology Company and Closes Concurrent Financing
  
• AIDS-related non-Hodgkin leukemia outcome is associated with Epstein-Barr viral load in whole blood
  
• Alexion launches EXPLORE study for severe anemia disorder
  
• Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
  
• Allo-SCT using cord blood or matched-sibling donors comparable in advanced Hodgkin lymphoma
  
• Allogeneic hematopoietic stem cell transplantation favors altered hypothalamic dopaminergic tone
  
• Allogeneic stem cell transplantation using umbilical cord blood or matched-sibling donors is comparable in adults with high-risk advanced Hodgkin's lymphoma
  
• Allogeneic Stem Cell Transplants May Be Best Option for Cutaneous T-Cell Lymphomas
  
• Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
  
• Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
  
• Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
  
• Almac Teams up with the Leukemia and Lymphoma Society
  
• Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
  
• AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data
  
• Amyloidosis, scarring of pulmonary vein myocardial sleeves is common in elderly
  
• An autologous vaccine expressing transgenic human CD40L and IL-2 provides immunotherapy of high-risk acute leukemia
  
• An Interactive Dialog on Myeloma, Lymphoma and Leukemia: Clinical Integration of Recent Advances was held in Scottsdale on May 20, 2006
  
• An orally active proteasome inhibitor induced apoptosis in multiple myeloma (MM) cells
  
• Angiogenesis cytokines accelerate endothelial-like cell differentiation
  
• Annual Mammography Alone Not Sufficient for Young Hodgkin’s Survivors
  
• AnorMED completes enrollment in phase III trial for Mozobil
  
• ANORMED COMPLETES ENROLLMENT IN PHASE III TRIAL FOR MOZOBIL IN STEM CELL TRANSPLANT IN MULTIPLE MYELOMA
  
• Antiestrogenic therapies proposed to treat solid cancers and multiple myeloma
  
• Antigen identified as possible immunotherapy for myeloid leukemias
  
• Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
  
• Antisoma Starts Phase II Trial of AS1411 in Acute Myeloid Leukaemia
  
• Apoptotic gene expression profiled in chronic lymphocytic leukemia
  
• Approval summary of nelarabine for T cell lymphoblastic leukemia and lymphoma is released
  
• Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia
  
• Arsenic trioxide boosts survival in leukemia
  
• Arsenic-based therapy shown to help eradicate leukemia-initiating cells
  
• ASCO Patient Guide: Bisphosphonates for Multiple Myeloma
  
• Atypical myeloproliferative disorders were discussed
  
• Atypical myeloproliferative disorders were discussed
  
• Autologous dendritic cells generated from leukemic blasts show promise as immunotherapy for patients with acute myeloid leukemia
  
• Autologous dendritic cells pulsed with necrotic tumor lysate generated in vitro B-CLL-specific HLA class I restricted CTL responses
  
• Autologous stem cell transplantation safe and effective in myeloma patients
  
• Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
  
• B cell chronic lymphocytic leukemia response to nutlin-3 should be studied
  
• B cell lymphoma could be linked to inactivation of the PR domain containing 1 with zinc finger domain (PRDM1)/B lymphocyte-induced maturation protein 1 (BLIMP1) gene
  
• B chronic lymphocytic leukemia cell interleukin production involves RANKL/RANK
  
• B-cell Chronic Lymphocytic Leukemia (B-CLL): Expanded Labeling for MabCampath in Europe
  
• B-cell chronic lymphocytic leukemia (CLL) finds hope in new therapeutic strategy that targets the Mdm2-p53 interaction
  
• B-cell depletion may enhance antitumor immune responses by decreasing IL-10 production from B cells
  
• B-cell lymphoma could be examined by automated analysis of fluorescence in situ hybridization
  
• B-precursor childhood acute lymphoblastic leukemia (ALL) could be linked to perforin (PRF1) polymorphism A91V but requires further study
  
• BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia
  
• BCR-ABL transcript level patterns after allograft is variable in chronic myeloid leukemia
  
• BCR-ABL transcript level patterns following stem cell transplantation is variable in patients with Philadelphia chromosome-positive chronic myeloid leukemia
  
• BCR-ABL transcript level patterns following stem cell transplantation is variable in patients with Philadelphia chromosome-positive chronic myeloid leukemia
  
• BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
  
• Better alternative to HLA typing as a genetic test for abacavir hypersensitivity syndrome reported
  
• Bexarotene is useful in the treatment of cutaneous T-cell lymphoma
  
• Bik/NBK accumulation correlates with apoptosis induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
  
• BIOCRYST INITIATES ENROLLMENT IN PIVOTAL TRIAL OF FORODESINE HCL IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
  
• BioCryst Pharmaceuticals, Inc., (BCRX) announced that it has initiated a pivotal trial of its lead oncology drug, Fodosine, in the treatment of patients with relapsed or refractory T-cell leukemia/lymphoma
  
• BioCryst Pharmaceuticals, Inc., (BCRX) announced the receipt of a Special Protocol Assessment (SPA) letter from the U.S. Food and Drug Administration (FDA) for Fodosine (forodesine hydrochloride)
  
• BioCryst Pharmaceuticals, Inc., (BCRX) provided an informational update summarizing highlights from an oral presentation related to the clinical development of forodesine hydrochloride (formerly referred to as Fodosine)
  
• BIOCRYST RECEIVES SPECIAL PROTOCOL ASSESSMENT FOR PIVOTAL TRIAL OF ORAL FODOSINE IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
  
• Bioenvision Provides Evoltra (clofarabine) Regulatory Update
  
• Biofeedback therapy helps some people control aspects of their body
  
• Blood cancer breakthroughs presented
  
• Blood Stem Cells Originate in the Placenta
  
• Bortezomib causes severe pulmonary complications in Japanese patients
  
• Bortezomib for injection shows positive results in newly diagnosed multiple myeloma patients
  
• Bosutinib: A New Kinase Inhibitior for Treatment of Philadelphia Chromosome Positive Leukemia
  
• Breast-feeding of more than 6 months could prevent childhood lymphoid malignancies, especially for acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML)
  
• Breastfeeding patterns were not linked to the risk of childhood acute lymphoblastic leukemia (ALL)
  
• Callisto Pharmaceuticals study of anti-leukemia drug L-Annamycin is expanded
  
• Can cancer drugs combine forces?
  
• Cancer Researchers at the University of Pennsylvania Discover What Makes Lymphomas Tick
  
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate documented
  
• Cases of chronic myelogenous leukemia and rheumatic disease linked
  
• Causes of male infertility investigated
  
• CD38 expression correlates with cell mutation status in chronic lymphocytic leukemia according to a study from the Netherlands
  
• Ceflatonin receives U.S. FDA orphan drug designation for treatment of chronic myeloid leukemia
  
• Celgene Corporation (CELG) announced that the European Medicines Agency (EMEA) has accepted for review the company's marketing authorization application (MAA) for lenalidomide in the treatment of multiple myeloma
  
• Cell Genesys Provides Update on Clinical Program for GVAX Immunotherapy for Leukemia
  
• Cell Therapeutics CHOP-Zevalin Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
  
• Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
  
• Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
  
• Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
  
• Cell-penetrating peptide are a vector for tracking mesenchymal stem cells
  
• Cellular transformation by human T-cell leukemia virus type 1 (HTLV-1) could be associated with TAX
  
• Cephalon Announces Plans For New NDA Filing For TREANDA(R)
  
• Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
  
• Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
  
• Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
  
• Challenges to identifying genetic determinants of pediatric cancers were discussed
  
• Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL) were analyzed
  
• Changes in multiple myeloma epidemiology in last 30 years reviewed
  
• ChemGenex Announces Positive Preliminary Data From Phase 2/3 Clinical Trial of Ceflatonin® at International Conference
  
• ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
  
• ChemGenex launches multinational phase 2/3 study for CML patients with T315I mutation
  
• ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced that positive clinical results supporting the development of Ceflatonin(R) in patients with chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced that positive clinical results supporting the development of Ceflatonin(R) in patients with chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals (CXS; CXSP) announced that it has launched a new multinational phase 2/3 study evaluating the use of Ceflatonin (homoharringtonine, HHT) in patients with chronic, accelerated and blast-phase chronic myeloid leukemia (CML)
  
• ChemGenex Pharmaceuticals Limited (CXS and CXSP) announced the presentation of new clinical data supporting the use of Ceflatonin (homoharringtonine or HHT) as a treatment for chronic myeloid leukemia (CML) patients who have developed resistance to Gleeve
  
• ChemGenex Pharmaceuticals Limited (CXS and CXSP) announced the recent publication of two clinical research papers that support the expansion of the clinical development of Ceflatonin to include treatment of both newly diagnosed acute myeloid leukemia (AML
  
• ChemGenex Pharmaceuticals Limited announced the publication of preclinical research supporting the expansion of its clinical development of Ceflatonin to include treatment of acute myeloid leukemia (AML) patients in addition to chronic myeloid leukemia (C
  
• ChemGenex presents data on Ceflatonin for treating CML patients resistant to Gleevec
  
• ChemGenex publishes two new clinical studies supporting Ceflatonin beyond CML to other leukemias
  
• ChemGenex Seeking Partners to Sell Leukemia Treatment
  
• ChemGenex teams with MolecularMD to identify CML patients with T315I drug resistance mutation
  
• Chemoimmunotherapy effective in elderly with chronic lymphocytic leukemia
  
• Chemotherapy plus Radiation Recommended as Standard of Care in Early Hodgkin’s
  
• Childhood acute myeloid leukemia (AML) survival was worse in Hispanic and black children than white children
  
• Childhood cancer survival prognostic factors identified
  
• Childhood Leukemia And Lymphoma Survivors Have Elevated Risk Of Second Cancers
  
• Childhood leukemia risk could be linked to birth weight, maternal weight, and factors that influence abnormal fetal growth patterns
  
• Childhood Leukemia Survivors Have Decreased Height in Adulthood
  
• Childhood lymphoid malignancies protected against by breast-feeding of more than 6 months
  
• Children and young people show elevated leukaemia rates near nuclear facilities
  
• Children's Hospital researcher leads multi-pronged attack on infant leukemia
  
• Chronic lymphocytic leukemia biology influenced by p53 polymorphisms
  
• Chronic lymphocytic leukemia cell survival is promoted by high Mda-7 expression
  
• Chronic lymphocytic leukemia displays a proangiogenic component
  
• Chronic lymphocytic leukemia displays a proangiogenic component
  
• Chronic lymphocytic leukemia treatment could be treated with weekly clofarabine
  
• Chronic myelogenous leukemia patients exhibit altered bone and mineral metabolism while receiving imatinib
  
• Chronic myelogenous leukemia therapy finds new target in Janus kinase 2
  
• Chronic myeloid leukemia (CML) imatinib treatment could be enhanced by valproate
  
• Chronic myeloid leukemia (CML) patients might experience molecular remission after imatinib mesylate treatment
  
• Chronic myeloid leukemia (CML) response to imatinib could be predicted by prospective quantitation of BCR-ABL transcript
  
• Chronic myeloid leukemia developed in a patient with primary thrombocythemia (PT) and absence of BCR/ABL rearrangement
  
• Chronic myeloid leukemia patient monitoring and methods for detecting BCR-ABL transcripts outlined
  
• Chronic myeloid leukemia patients to benefit from promising new drug
  
• Chronic myeloid leukemia response to imatinib predicted by quantitation of BCR-ABL transcript
  
• cIAP2 disfunction was implicated in mucosa-associated lymphoid tissue (MALT) lymphomas
  
• CIGNA HealthCare Teams with HopeLab to Help Blast Teen Cancer
  
• Cleveland BioLabs, Inc. (CBLI) announced that through its research in the area of radiation protection, the company has discovered a unique property of its Protectans 600 series, which has lead to a major breakthrough in the stem cell arena
  
• Clinical Challenges in the Management of Acute Myeloid Leukemia: Peer-to-Peer Forums for Improving Patient Care
  
• Clinical Challenges in the Management of Acute Myeloid Leukemia: Peer-to-Peer Forums for Improving Patient Care
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clofarabine and cytarabine induction therapy was active in acute myeloid leukemia (AML) patients 50 years of age or older, warranting further evaluation
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• Clone-specific PCR assesses minimal residual disease in patients with hairy cell leukemia
  
• CombiMatrix Molecular Diagnostics Launches HemeScan Ploidy Test for the Management of Acute Lymphoblastic Leukemia
  
• Combination Therapy Effective Against Multiple Myeloma
  
• Complete remission before autografting predicts better survival in patients with advanced stage peripheral T-cell lymphoma
  
• Complex chromosomal rearrangements (CCR) were detected in patients with chronic myeloid leukemia (CML)
  
• Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells
  
• Coping was linked to survival in leukemia patients undergoing allogeneic bone marrow transplantation (BMT)
  
• Cord blood research advances have been reported from the United States and Netherlands
  
• Cord blood transplants OK for leukemia
  
• Curacyte receives European Orphan Drug Designation for its PDE-4 inhibitor in Chronic Lymphocytic Leukemia
  
• CuraGen and TopoTarget announce initiation of first NCI-sponsored clinical trial with PXD101
  
• CuraGen and TopoTarget announce NCI-sponsored Phase II clinical trial with PXD101 for AML
  
• CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
  
• CuraGen and TopoTarget present new preclinical data on PXD101 in treating cancer
  
• CuraGen Announces Top-Line Phase II Results on Velafermin
  
• CuraGen Corporation (CRGN) and TopoTarget A/S announced that the companies have reviewed interim efficacy and safety data from the ongoing open-label trial evaluating belinostat (PXD101) monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL)
  
• CuraGen Presents Update on Clinical Development Program for Belinostat
  
• Current study results from the report, "Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature," have been published
  
• Current study results from the report, "Benzene exposure and risk of non-Hodgkin lymphoma," have been published
  
• Current study results from the report, "Benzene exposure and risk of non-Hodgkin lymphoma," have been published
  
• Current study results from the report, "Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma," have been published
  
• Current study results from the report, "Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability," have been published
  
• Current study results from the report, "Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide," have been published
  
• Cyclacel Reports Phase I Sapacitabine Data in Patients with Advanced Leukemias and Myelodysplastic Syndromes at 2007 ASCO Annual Meeting
  
• Cyclophosphamide and fludarabine could be used to treat chronic lymphocytic leukemia (CLL)
  
• Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
  
• Cytogenetic response to prior IFN treatment predicts survival after AHSCT in CML
  
• Cytokinetics, Incorporated (CYTK) announced that a poster summarizing non-clinical data evaluating ispinesib (SB-715992), a novel inhibitor of the mitotic kinesin, kinesin spindle protein (KSP), in cellular models of multiple myeloma
  
• Daisies lead scientists down path to new leukemia drug
  
• Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
  
• Dasatinib studied in patients with leukemia and resistance or intolerance to imatinib
  
• Dasatinib targets earlier progenitors than imatinib in primary chronic myeloid leukemia
  
• Data at ASCO demonstrate potential of Velcade for injection across solid and hematological cancers
  
• Data detailed in "Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance" have been presented
  
• Data detailed in "Findings of fluorine-18-FDG PET in extranodal origin lymphoma--in three cases of diffuse large B cell type lymphoma" have been presented
  
• Data detailed in "Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression" have been presented
  
• Data detailed in "Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression" have been presented
  
• Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting
  
• Data from Phase I clinical trial of Quadramet in patients with relapsed multiple myeloma presented
  
• Data from University of Pennsylvania, Abramson Cancer Center advance knowledge in lymphoma therapy
  
• Data on acute myelomonocytic leukemia published by researchers at Nagoya University
  
• Data on chronic myeloid leukemia therapy reported by researchers at Institute for Medical Informatics
  
• Data on leukemia are outlined in reports from the United States and Spain
  
• Data on leukemia therapy reported by researchers at Zhejiang University, Cancer Institute
  
• Data on lymphoma immunotherapy discussed by researchers at Nagoya City University, Department of Internal Medicine
  
• Data Show Geron’s Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
  
• Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment In Patients With Follicular Lymphoma
  
• Decision Fails Patients with Transfusion-Dependent Anemia
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dehydroxymethylepoxyquinomicin (DHMEQ), a new NF-kappa B inhibitor, could induce apoptosis in chronic lymphocytic leukemia (CLL)
  
• Dendritic cell-based vaccine generated for B-cell chronic lymphocytic leukemia
  
• Dendritic cells expand Epstein-Barr-specific CD8 T cell responses more efficiently than EBV-transformed B cells
  
• Dendritic cells from multiple myeloma patients have impaired functionality
  
• Dendritic cells from patients with multiple myeloma have impaired functionality and phenotypic profile
  
• Denileukin Receives Fast-Track Approval for Treatment of Cutaneous T-Cell Lymphoma (CTCL)
  
• Denosumab was well tolerated and reduced bone resorption for at least 84 days
  
• Detection of bone marrow lesions was improved by ferumoxtran-10-enhanced MR imaging
  
• Diagnosis of secondary malignancies after successful primary treatment of malignant Hodgkin lymphoma (HL) could be difficult
  
• Different gamma/delta T clones sustain GVM and GVH effects after non-myeloablative transplantation
  
• Discovery major step forward in treating leukemia
  
• Distribution of follicular dendritic cell (FDC) in mantle cell lymphoma (MCL) could be linked to better clinical prognosis
  
• Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
  
• DNA hypomethylation occurred after 5-aza-2'-deoxycytidine (decitabine) therapy at low doses in leukemia patients
  
• DNA hypomethylation occurred after 5-aza-2'-deoxycytidine (decitabine) therapy at low doses in leukemia patients
  
• Doctors Report High Survival Rates for Hodgkin's Disease
  
• Donor isohemagglutinin is not produced in patients undergoing minor ABO incompatible umbilical cord blood transplantation
  
• Donor lymphocyte infusions effective for treatment of relapsed disease after ASCT
  
• Doxil® Approved for Multiple Myeloma in Combination with Velcade®
  
• Drug aids relapsed lymphoma patients
  
• Drug combination slows the progression of treatment resistant bone marrow cancer
  
• Drug Combo Effective Against Leukemia
  
• Drug has ability to cure type of leukemia
  
• Drug resistance argues against mutation theory of cancer
  
• Drug that battles resistance to leukemia pill Gleevec shown to be effective against cancer
  
• Drug Therapy Superior to Stem Cell Transplantation for CML
  
• Early BCR-ABL Kinase Inhibition Points to Leukemia Imatinib Response
  
• Early embryonic stem cell differentiation involves a protein kinase
  
• Early lymphocyte recovery predicts longer survival after stem cell transplantation
  
• Early multiple myeloma diagnosis and patient referral to oncologist recommended
  
• Early-onset thyrotoxicosis occurs after unrelated umbilical cord blood transplantation in acute myelogenous leukemia
  
• Easier to predict the future for leukemia patients
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• EBV-associated gastric diffuse large B-cell lymphomas might be resistant to standard chemoradiotherapy
  
• Eculizumab Does Not Increase Risk of Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders: Presented at ASCO
  
• Effects of aging in stem cells
  
• Efficacy of shipped HLA-matched platelets is reported
  
• Elderly AML Patients Benefit More from Prolonged Post-Remission Therapy
  
• EMEA Grants Orphan Drug Designation To BioCryst's Fodosine(TM) For The Treatment Of Cutaneous T-Cell Lymphoma (CTCL)
  
• Emerging Therapies for CML (Video)
  
• Emory researchers identify signaling protein for multiple myeloma
  
• ENTREMED COMMENCES LEUKEMIA CLINICAL TRIAL FOR MKC-1 IN CANADA
  
• Enzon Pharmaceuticals initiates Oncaspar Phase I solid tumor trial
  
• EpiCept Accelerates Development of EPC2407 for Cancer
  
• EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
  
• EpiCept Reports Regulatory Progress on Ceplene(TM)
  
• European Commission Grants Orphan Drug Designation to Xanthus' Xanafide for the Treatment of Acute Myeloid Leukemia
  
• Exercise Rate Low in Childhood Leukemia Survivors
  
• Experimental Drug Shows Promise in Treating One Class of Lymphoma
  
• Experts Outline Use of Bisphosphonates Against Myeloma
  
• Exploring The Mechanisms Of Leukemia EHA Congress 2007
  
• Expression of CT45 in Hodgkin lymphoma is characterized
  
• Extracellular KIT receptor mutants, found in acute myelogenous leukemia (AML), respond to imatinib mesylate
  
• Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
  
• FDA Approves Expanded Labeling for Campath to Include First-line Treatment for Leading Form of Adult Leukemia
  
• FDA Approves New Product to Treat Von Willebrand Disease
  
• FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
  
• FDA Approves Nilotinib for Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
  
• FDA approves vorinostat (Zolinza) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)
  
• FDA Extends Review Of GENASENSE NDA Appeal in Chronic Lymphocytic Leukemia
  
• FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
  
• FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
  
• FDA Okays Sprycel for CML Resistant or Intolerant to Gleevec
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene replacement therapy using a chimeric adenovirus shows promise for leukemia
  
• FHIT gene therapy using chimeric adenovirus shows promise for leukemia
  
• Fibroblast activation protein is a potential therapeutic target in myeloma
  
• Findings from Cell Signaling Technology, Inc. advance knowledge in acute myeloid leukemia genetics
  
• Findings from Children's Hospital in lymphoma in children reported
  
• Findings from Italy and Japan in leukemia provide new insights
  
• Findings from Peking Union Medical College, Medical College provide new insights into leukemia genetics
  
• Findings from the United States and United Kingdom describe new data in leukemia research
  
• Findings from University of Arizona, Arizona Cancer Center provide new insights into myelodysplastic syndrome
  
• Findings from University of Oslo, Biotechnology Center advance knowledge in waldenstrom macroglobulinemia
  
• FIREFLY GENES ALLOW TESTING OF NEW THERAPY AGAINST LYMPHOMA
  
• First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
  
• First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx(R) for Leukemia and Lymphoma
  
• Flow cytometry and quantitative PCR assesses minimal residual disease more accurately than consensus PCR in patients with chronic lymphocytic leukemia who underwent stem cell transplantation
  
• FLT3 D324N variant may be associated with a predisposition to different leukemia subtypes
  
• Fludara and Cytoxan Confirmed Standard Initial Treatment for CLL
  
• Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
  
• Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin treatment is well tolerated in refractory and/or relapsed adult acute lymphoblastic leukemia
  
• Fludarabine-based regimen allows sustained engraftment without immediate toxicity
  
• Fludarabine-based regimen without irradiation is effective in patients with Fanconi anemia who are undergoing HLA-matched related donor hematopoietic cell transplantation
  
• Fms-like tyrosine kinase 3/ITD is a relevant marker for acute myeloid leukemia prognosis
  
• FoldRx Announces Its Phase II/III Clinical Study with Lead Clinical Candidate
  
• Forever young: Differentiation blocked in tumor stem cells
  
• Four additional cancer centers join Multiple Myeloma Research Consortium
  
• Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study
  
• Fresh data on acute lymphoblastic leukemia are presented in the report "Cytogenetic patterns in ETV6/RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia
  
• Fresh data on B-cell lymphoma are presented in the report "DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma
  
• Fresh data on leukemia are presented in the report "Pharmacological inhibition of the MAPK/ERK pathway increases sensitivity to 2-chloro-2'-deoxyadenosine (CdA) in the B-cell leukemia cell line EHEB."
  
• Fresh data on lymphoma are presented in the report "Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-re